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Objectives
Dolutegravir (DTG) is a highly effective integrase inhibitor with a strong genetic resistance barrier
and a potential role in simplified HIV maintenance treatment. We assessed the feasibility of DTG
maintenance monotherapy and measured HIV reservoirs on DTG monotherapy.
Methods
An interventional, open-label, single-arm study including eight virologically suppressed HIV-1-
infected patients switched to DTG 50 mg once daily for 24 weeks was performed. HIV-1 RNA
levels in plasma and cerebrospinal and seminal fluids were measured at baseline and week 24, as
well as HIV-1 DNA in peripheral cells and DTG concentrations in these compartments.
Results
HIV-1 RNA remained undetectable in all samples of blood, cerebrospinal fluid and sperm
throughout the 24 weeks, except for one cerebrospinal fluid sample with a value of 28 HIV-1 RNA
copies/mL at week 24. One patient discontinued the study because of a neurological side effect.
There was no change in the mean HIV-1 DNA level between baseline and week 24. Plasma and
cerebrospinal fluid DTG concentrations reached therapeutic levels in all patients in these two
compartments.
Conclusions
In this small sample of carefully selected patients, HIV-1 reservoirs were well controlled on DTG
monotherapy over a period of 24 weeks. Viral suppression was also maintained throughout follow-
up.
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Introduction
Current HIV treatment changes are mainly driven by the
need for regimen simplification and toxicity issues. Reg-
imen optimization is also critical to further scaling up
of treatment and to support retention in care, particu-
larly in low- and middle-income settings [1]. Dolute-
gravir (DTG) is a highly effective and well-tolerated
integrase inhibitor. The SINGLE, FLAMINGO and
SPRING 2 randomized controlled studies have shown
the superiority of DTG at week 48 compared with efa-
virenz and ritonavir-boosted darunavir, as well as its
noninferiority to raltegravir in antiretroviral drug com-
binations among treatment-na€ıve HIV-1-infected patients
[2–4]. DTG was also found to be superior to raltegravir
among treatment-experienced patients with resistance to
at least two classes of antiretroviral drugs [5]. No resis-
tance to integrase inhibitors or the associated nucleotide
backbone has been described in treatment-na€ıve patients
included in these trials. In treatment-experienced
patients, initial or subsequent integrase mutations did
not result in high-level resistance to DTG, suggesting a
high genetic barrier at least similar to that of boosted
protease inhibitors [6].
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SHORT COMMUNICATION
The aim of our study was to assess the feasibility of
treatment simplification with DTG maintenance
monotherapy in virologically suppressed patients on
combination antiretroviral therapy (cART), and to mea-
sure HIV reservoirs by quantifying total HIV-1 DNA in
peripheral blood mononuclear cells (PBMCs) and HIV-1
RNA in plasma, cerebrospinal fluid (CSF) and seminal
fluid from patients on DTG monotherapy as well as DTG
concentrations in these compartments. We also investi-
gated the effect of DTG monotherapy on lipodystrophy
features, bone mineral density and immune activation.
Methods
We conducted an interventional, open-label, single-arm
study in which participants were switched to DTG
monotherapy 50 mg once daily for a duration of
24 weeks (the MONODO study). We included HIV-
1-infected patients > 18 years of age who had HIV-1
RNA < 50 HIV-1 RNA copies/mL plasma for at least
6 months on first-line cART. Previous changes of
antiretroviral drugs because of toxicity or for simplifica-
tion were allowed. Eligible participants had no history of
previous virological failure on cART or documented drug
resistance. All patients provided written informed con-
sent. The study was approved by the research ethics com-
mittee of Geneva, Switzerland, and registered on
clinicaltrials.gov (NCT02572947).
Participants consented to provide CSF and sperm sam-
ples at baseline and week 24, although lumbar puncture
was optional at baseline. Study visits were scheduled on
a monthly basis with a plasma HIV-1 RNA quantification
performed at each visit, as well as an adherence evalua-
tion performed using pill count and validated question-
naires. The following tests were performed at baseline
and week 24: determination of HIV-1 RNA in plasma,
CSF and seminal fluid using polymerase chain reaction
(PCR) with a limit of detection of 20 copies/mL (COBAS
AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0; Roche Diag-
nostics, Rotkreuz, Switzerland); total HIV-1 DNA quan-
tification in PBMC samples using digital droplet PCR;
measurement of DTG concentrations in plasma, CSF and
sperm by liquid chromatography coupled to tandem mass
spectrometry (LC-MS/MS); dual-energy X-ray absorp-
tiometry (DXA) scans and anthropometric measurements;
and biochemistry and measurement of inflammatory and
hypercoagulability markers. The primary outcome was
the proportion of patients completing 24 weeks of DTG
monotherapy without experiencing virological failure,
defined as plasma HIV-1 RNA ≥ 200 copies/mL or detect-
able HIV RNA in CSF. We compared outcome variables
between baseline and week 24 using a paired sample
t-test. We used Wilcoxon’s signed rank test for nonpara-
metric data. All statistical analyses were performed using




Eight patients (five men, two women and one transgender
patient) were included in the study from June 2015 to
December 2016. The mean age was 47.4 years (median
44.5; range 36–66 years). Mean durations of HIV-1 infec-
tion and ART before enrolment were 11.9 years (median
10.5; range 2–26 years) and 9.7 years (median 8.7; range
2.2–19.4 years), respectively. Seventy-five per cent (six of
eight) of participants were treated with a combination of
tenofovir, emtricitabine and a non-nucleoside reverse
transcriptase inhibitor prior to the switch. The mean
zenith viral load was 5.4 log copies/mL (median 5.4;
range 4.6–7 log copies/mL) and the mean nadir CD4
count was 301 cells/lL (median 305; range 21–555 cells/
lL).
Virological outcomes
Seven of eight patients (87.5%) completed the study. Of
these, all had undetectable plasma HIV-1 RNA (< 20
copies/mL) throughout the 24 weeks of follow-up
(Table 1). Therefore, our intention-to-treat plasma viro-
logical success at week 24 was 87.5%.
Mean adherence was 98.6% (median 99.4%; range
94.7–100%). Mean change in CD4 count from baseline
to week 24 was 28 cells/lL [95% confidence interval
(CI) 100 to 157 cells/lL; P = 0.6]. Six patients under-
went lumbar puncture at week 24 and one provided a
CSF sample at baseline. HIV-1 RNA was undetectable
in all samples except one, with a value of 28 HIV-1
RNA copies/mL after 24 weeks of DTG monotherapy.
Sperm samples were available for five and four men at
baseline and week 24, respectively. HIV-1 RNA in sem-
inal fluid was undetectable in all samples with a detec-
tion threshold of 40 or 80 copies/mL according to the
sample dilution. We were able to measure total HIV-1
DNA in PBMCs both at baseline and at week 24 in five
patients. No significant change was observed in mean
HIV-1 DNA level between the two time-points (42.1
HIV-1 DNA copies/106 genomic equivalents; 95% CI
127.3 to 211.6 DNA copies/106 genomic equivalents;
P = 0.5) (Table 1).
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Safety data
One participant discontinued the study because of mild
recurrent anxiety and hallucinations. The patient had
never used DTG previously. The first episode of symptoms
occurred during the first month of treatment and lasted
24 h. The patient recovered spontaneously. At week 12,
the patient experienced similar symptoms and asked to
withdraw from the study. The DTG plasma concentration
at week 12 was measured as being below the 10th per-
centile (569 ng/mL, 12 h after DTG intake). We suspected
that the symptoms were related to illicit drug intake.
For the remaining seven patients, the mean plasma
DTG concentration was 1764 ng/mL blood (median 2088;
range 145–3100 ng/mL), well above the protein-adjusted
90% inhibitory concentration (IC90) of 64 ng/mL. Mea-
surements were made between 8 and 23.5 h after drug
intake. In terms of percentiles, these values were above
the 50th percentile for four patients, but below the 10th
percentile for three others. We measured the CSF DTG
concentration at week 24 for six patients, and the mean
value was 9.0 ng/mL (median 9.7; range 5.4–12.6 ng/mL)
(Table 2).
Finally, we observed that participants gained weight
while on DTG monotherapy, with a mean increase in
weight of 4.1 kg (95% CI 1.4–6.9 kg; P = 0.01) from
baseline to week 24. However, there was no significant
change in visceral or subcutaneous adipose tissues from
baseline to week 24 as measured by DXA scans. Full
results for safety parameters are presented in Table 2.
At the end of the study, five participants remained on
DTG monotherapy, one was switched to dual therapy
with DTG and emtricitabine and two, including the
patient who withdrew from the study, were switched back
to cART. All had an undetectable plasma HIV RNA after
48 weeks of follow-up.
Discussion
In this small study, HIV-1 RNA remained undetectable in
the plasma, CSF and sperm of selected patients who
received DTG monotherapy as maintenance treatment
throughout 24 weeks of follow-up. One patient had
detectable HIV-1 RNA in the CSF at week 24 with a value
of 28 copies/mL. This result was not considered to be a
virological failure as this value could not be repeated and
was close to the detection limit of the test. Moreover, this
patient had undetectable plasma HIV-1 RNA during the
entire follow-up and DTG plasma and CSF concentrations
at week 24 were 2104 and 5.4 ng/mL, respectively. The
patient reported minor side effects of fatigue and anxiety
at the end of the study and he was switched back to DTG
and emtricitabine without any further problems reported.
One patient withdrew from the study at his request
Table 1 Results by study participant for HIV-1 RNA and dolutegravir (DTG) concentrations in plasma, cerebrospinal fluid and sperm, and total
HIV-1 DNA in peripheral blood mononuclear cells
MONODO patient ID
01 02 03 04 05 06 07 08
Plasma HIV-1 RNA (copies/mL) Baseline < 20 < 20 < 20 < 20 < 20 < 20 < 20 < 20
Week 4 < 20 < 20 < 20 < 20 < 20 < 20 < 20 < 20
Week 8 < 20 < 20 < 20 < 20 < 20 < 20 < 20 < 20
Week 12 < 20 < 20 < 20 < 20 < 20 < 20 < 20 < 20
Week 16 < 20 < 20 < 20 < 20 < 20 < 20 < 20 NA*
Week 20 < 20 < 20 < 20 < 20 < 20 < 20 < 20 NA*
Week 24 < 20 < 20 < 20 < 20 < 20 < 20 < 20 NA*
CSF HIV-1 RNA (copies/mL) Baseline NA† < 20 NA† NA† NA† NA† NA† NA†
Week 24 < 20 < 20 < 20 28 < 20 NA < 20 NA*
Seminal fluid HIV-1 RNA (copies/mL)¶ Baseline < 40 NA‡ NA‡ < 40 < 40 < 40 NA‡ < 80
Week 24 < 80 NA‡ NA‡ < 40 < 40 < 40 NA‡ NA*
Total HIV-1 DNA in PBMCs
(DNA copies/106 genomic equivalents)††
Baseline NA§ 170.9 NA§ 205.8 185.6 248.6 67.2 NA§
Week 24 NA§ 108.9 NA§ 279.1 72.0 483.3 145.5 NA*
DTG concentration at week 24 (ng/mL) Plasma 367 2088 1707 2104 2834 145 3100 NA*
CSF 9 10.4 6.1 5.4 10.4 NA 12.6 NA*
Seminal fluid 0 NA‡ NA‡ 84 205 0 NA‡ NA*
ID, identification; NA, not available; CSF, cerebrospinal fluid; PBMCs, peripheral blood mononuclear cells.
*Patient discontinued the study at week 12.
†Lumbar puncture optional at baseline.
‡Female or transgender: no sperm sample possible.
§Missing data.
¶The limit of quantification in seminal fluid is 40 copies/mL because of sample dilution.
††HIV-1 DNA and the single-copy host gene C-C chemokine receptor type 5 (CCR5) were quantified by digital droplet polymerase chain reaction in
parallel. Cell counts are displayed as genomic equivalents as defined by two CCR5 copies per genomic equivalent (cell).
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because of side effects. Therefore, our intention-to-treat
virological success at week 24 was 87.5%.
These results are similar to those reported in observa-
tional studies of DTG monotherapy throughout 24 weeks,
which ranged from 89% to 97% [7–9]. However, a large
randomized controlled trial of DTG maintenance
monotherapy showed that, while DTG monotherapy was
noninferior to cART at 24 weeks, most virological failures
occurred after week 24 and could lead to integrase inhi-
bitor-associated mutations [10]. A meta-analysis of sim-
plified DTG maintenance therapy confirmed these
findings and reported that DTG maintenance monother-
apy led to a relevant risk of virological failure in 220
participants on this treatment. The proportion who expe-
rienced virological failure was 3.2% (95% CI 1.5–6.5%)
and 8.9% (95% CI 4.7–16.2%) at weeks 24 and 48,
respectively [11]. Moreover, 50% of patients who experi-
enced failure developed resistance to the integrase inhibi-
tor class.
In our study, we quantified total HIV-1 DNA in
PBMCs and DTG concentrations in different compart-
ments. Total HIV-1 DNA levels in PBMCs were low at
baseline with no significant change during follow-up.
Our measurement amplified integrated and unintegrated,
and replication competent as well as defective viral
DNA. First, it has been shown that total HIV-1 DNA
measurement in patients on successful cART for
> 6 months mainly reflects integrated HIV-1 DNA, as
unintegrated HIV-1 DNA largely vanishes within the
first few months on cART [12], and that defective
forms facilitate the persistence of HIV reservoirs in the
body [13]. Secondly, total HIV-1 DNA is considered as
a sensitive and clinically relevant biomarker for the
HIV-1 reservoir and low levels of total HIV-1 DNA
indicate low risks of disease progression, viral rebound
and development of drug resistance [13]. Furthermore,
HIV RNA remained under the limit of detection in all
samples of seminal fluid. Similar genital shedding and
residual viraemia were also observed among patients
on simplified maintenance regimens, including DTG
monotherapy, compared with those on cART [14]. These
data suggest that DTG monotherapy is sufficient to
contain the peripheral HIV reservoir on a short-term
basis.
Plasma DTG concentrations exceeded the protein-
adjusted IC90 of 64 ng/mL for all patients in our study
[15,16]. In the CSF, the median DTG concentration at
week 24 was 9.7 ng/mlL (range 5.4–12.6 ng/mL). All val-
ues exceeded the in vitro 50% inhibitory concentration
for wild-type HIV (0.2 ng/mL) as described by Letendre
Table 2 Safety parameters, anthropometric measurements, dual-energy X-ray absorptiometry (DXA) scan values and inflammatory markers at




24 (95% CI) P-value
Immunological measurement
CD4 count (cells/lL) [mean ( SD, median)] 800 ( 380, 743) 842 ( 349, 974) 28 (100, +157) 0.6
Biochemistry measurements
Creatinine (lmol/L) [mean ( SD, median)] 80.5 ( 16.9, 77.5) 82.6 ( 6.2, 84.0) 7.1 (4.4, +18.7) 0.2
ALAT (UI/L) [mean ( SD, median)] 34.4 ( 26.2, 21.5) 30.4 ( 13.0, 29.0) 4.7 (8.1, +17.6) 0.4
Total cholesterol (mmol/L) [mean ( SD, median)] 4.6 ( 0.7, 4.7) 5.2 ( 1.8, 4.9) 0.6 (1.2, +2.4) 0.4
HDL cholesterol (mmol/L) [mean ( SD, median)] 1.3 ( 1.0, 0.9) 1.2 ( 0.6, 1.2) 0.2 (1.0, +0.65) 0.6
Triglycerides (mmol/L) [mean ( SD, median)] 1.4 ( 0.6, 1.3) 2.1 ( 1.6, 1.5) 0.6 (0.6, +1.9) 0.3
Anthropometric and fat distribution measurements
Weight (kg) [mean ( SD, median)] 79.2 ( 14.3, 84.7) 85.3 ( 15.4, 87.5) 4.1 (+1.4, +6.9) 0.01
BMI (kg/m2) [mean ( SD, median)] 27.1 ( 4.6, 26.8) 28.5 ( 4.9, 28.3) 1.1 (+0.1, +2.0) 0.03
Waist/hip ratio [mean ( SD, median)] 0.95 ( 0.09, 0.94) 0.95 ( 0.07, 0.97) 0.01 (0.09, +0.07) 0.8
Visceral adipose tissue (cm2) [mean ( SD, median)] 129.2 ( 76.4, 102.5) 124.1 ( 50.7, 115.5) 15.7 (61.9, +30.4) 0.4
Subcutaneous adipose tissue (cm2) [mean ( SD, median)] 223.4 ( 102.4, 223.4) 277.6 ( 117.4, 243.6) 32.2 (13.1, +77.4) 0.1
Bone density measurements
L1-L4 T-score [mean ( SD, median)] 0.75 ( 0.98, 0.45) 1.07 ( 1.04, 1.3) 0.13 (0.50, +0.24) 0.4
Femoral neck T-score [mean ( SD, median)] 0.66 ( 0.67, 0.75) 0.64 ( 0.52, 0.6) 0.17 (0.11, +0.35) 0.06
Hip T-score [mean ( SD, median)] 0.09 ( 0.39, 0.2) 0.01 ( 0.47, 0.2) 0.03 (0.24, +0.19) 0.8
Inflammatory and hypercoagulability markers
hs-CRP (mg/L) [mean ( SD, median)] 2.5 ( 3.3, 0.9) 7.5 ( 12.6, 1) 5.1 (6.6, +16.7) 0.3
TNF-a (pg/mL) [mean ( SD, median)] 2.8 ( 1.1, 2.6) 3.6 ( 1.7, 2.9) 0.8 (0.4, +2.1) 0.2
MCP1/CCL2 (pg/mL) [mean ( SD, median)] 267.4 ( 86.0, 265.0) 242.0 ( 68.1, 273.4) 20.7 (78.2, +36.9) 0.4
Insulin (UI/L) [mean ( SD, median)] 11.7 ( 6.6, 10.5) 62.4 ( 129.3, 15.3) 49.5 (65.7, +164.7) 0.3
D-dimers (lg/L) [mean ( SD, median)] 337.8 ( 296.1, 259.5) 455 ( 477.2, 232) 110.4 (103.9, +324.8) 0.2
ALAT, alanine transaminase; BMI, bone mineral index; CI, confidence interval; hs-CRP, high-sensitivity C-reactive protein; HDL, high-density lipoprotein;
SD, standard deviation; TNF, tumour necrosis factor; MCP1/CCL2, monocyte chemoattractant protein 1.
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et al. [17], thus suggesting a therapeutic concentration in
this compartment.
We also demonstrated that DTG was safe and led to
no change in the CD4 cell count, kidney or liver func-
tions, lipid profile, bone mineral density or markers of
inflammation and hypercoagulability. DTG is known to
be lipid-neutral compared with efavirenz or boosted
darunavir [3,4]. We observed no reduction in the level
of cardiovascular biomarkers or benefits for bone min-
eral density as described with raltegravir after switching
from a protease inhibitor [18,19], but none of our par-
ticipants had received this class of drug prior to study
enrolment. We found a significant increase in weight,
with a mean gain of 4.1 kg in 24 weeks, and body
mass index among our participants on DTG monother-
apy. Similarly, a retrospective study showed that
patients who switched from an efavirenz- to an inte-
grase-based regimen gained an average of 2.9 kg at
18 months compared with 0.9 kg for those who contin-
ued on efavirenz (P = 0.003); those who switched to
DTG gained the most weight (+ 5.3 kg) [20]. The poten-
tial correlation with lipodystrophy needs to be evalu-
ated in the long term.
Our study has several limitations. The sample size was
small, the study duration was short and it was a single-
arm study. In addition, we could not compare DTG main-
tenance monotherapy with cART. Participants were rigor-
ously selected with no prior documented ART failure,
which renders it difficult to generalize our results.
Conclusions
In our study, HIV reservoirs in PBMCs, CSF and sperm
remained stable over a period of 24 weeks in selected
patients switched to DTG maintenance monotherapy. As
virological failures mostly occur after 24 weeks of fol-
low-up, DTG maintenance monotherapy is not a switch
strategy option in the long-term. However, DTG remains
a good candidate for simplified dual therapy in virologi-
cally suppressed patients.
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